FDA Patient Listening Session for CGD

On August 11, 2025, several CGD patients and caregivers shared their experiences during a Patient-Led Listening Session with the U.S. Food and Drug Administration (FDA) so its members could learn more about the symptoms, treatment options, challenges in getting a diagnosis, as well as the complex care needed for a child with a rare disease and its impact on the child and entire family.

Thank you to our CGDAA community members who shared their personal stories, advocated for more treatment options, and provided valuable insights.